Research By Anjaparavanda Naren, PhD
Post Date: August 12, 2019 | Publish Date: July 16, 2019
“Our technology closely resembles the human pancreas and potentially may help us find therapeutic measures to manage glucose imbalance in people with CF, which is linked to increased illness and death.”
Microfluidic devices have existed since 1979. But innovations in their design and functionality, especially since the advent of organoid technology, now allow researchers to bioengineer human organ tissues and mimic the function of natural organs in a laboratory setting.
The Cincinnati Children’s research team, which includes Naren and study first author Kyu Shik Mun, PhD, plans to use the devices in a pilot study to test FDA-approved drugs that modulate CFTR gene expression.
|Original Title:||Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders|
|Published in:||Nature Communications|
|Publish date:||July 16, 2019|
Anjaparavanda Naren, PhD
Research Director, Cystic Fibrosis Research Center
The Naren lab seeks to identifying interactions between the CFTR gene and its binding partners and to define how spatiotemporal regulation of CFTR-containing macromolecular complexes in the apical compartment of polarized epithelial cells lining the secretory epithelia regulates overall fluid secretion.
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.